These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32725283)

  • 21. Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.
    Burger ME; Fachineto R; Alves A; Callegari L; Rocha JB
    Brain Res; 2005 Jan; 1031(2):202-10. PubMed ID: 15649445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors.
    Sonego AB; Prado DS; Vale GT; Sepulveda-Diaz JE; Cunha TM; Tirapelli CR; Del Bel EA; Raisman-Vozari R; Guimarães FS
    Brain Behav Immun; 2018 Nov; 74():241-251. PubMed ID: 30217539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide.
    Naidu PS; Kulkarni SK
    Behav Pharmacol; 2001 Jun; 12(3):209-16. PubMed ID: 11485057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gamma-decanolactone: Preliminary evaluation as potential antiparkinsonian drug.
    Pflüger P; Pereira P; Loza MI; Brea J; Viña D; Kumar A; Fontenla JA
    Eur J Pharmacol; 2021 Sep; 906():174276. PubMed ID: 34174267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parallels between behavioral and neurochemical variability in the rat vacuous chewing movement model of tardive dyskinesia.
    Bachus SE; Yang E; McCloskey SS; Minton JN
    Behav Brain Res; 2012 Jun; 231(2):323-36. PubMed ID: 22503783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (-) Epigallocatechin-3-gallate attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum.
    Wang MH; Lin RF; Tseng HC; Soung HS; Chang KC; Tsai CC
    Pharmacol Biochem Behav; 2015 Apr; 131():71-6. PubMed ID: 25668129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing.
    Marchese G; Casu MA; Bartholini F; Ruiu S; Saba P; Gessa GL; Pani L
    Eur J Neurosci; 2002 Apr; 15(7):1187-96. PubMed ID: 11982629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
    Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
    Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of topiramate on oral dyskinesia induced by reserpine.
    Araujo NP; Abílio VC; Silva RH; Pereira RC; Carvalho RC; Gonzalez C; Bellot RG; Castro JP; Fukushiro DF; Rodrigues MS; Chinen CC; Frussa-Filho R
    Brain Res Bull; 2004 Dec; 64(4):331-7. PubMed ID: 15561468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats.
    Fachinetto R; Villarinho JG; Wagner C; Pereira RP; Puntel RL; Paixão MW; Braga AL; Calixto JB; Rocha JB; Ferreira J
    Psychopharmacology (Berl); 2007 Oct; 194(3):423-32. PubMed ID: 17641876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bauhinia forficata prevents vacuous chewing movements induced by haloperidol in rats and has antioxidant potential in vitro.
    Peroza LR; Busanello A; Leal CQ; Röpke J; Boligon AA; Meinerz D; Libardoni M; Athayde ML; Fachinetto R
    Neurochem Res; 2013 Apr; 38(4):789-96. PubMed ID: 23377855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia.
    Wang MH; Yang CC; Tseng HC; Fang CH; Lin YW; Soung HS
    Neurotox Res; 2021 Jun; 39(3):774-786. PubMed ID: 33523404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol.
    Egan MF; Hurd Y; Ferguson J; Bachus SE; Hamid EH; Hyde TM
    Psychopharmacology (Berl); 1996 Oct; 127(4):337-45. PubMed ID: 8923569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum.
    Burger ME; Alves A; Callegari L; Athayde FR; Nogueira CW; Zeni G; Rocha JB
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):135-40. PubMed ID: 12551736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoradiographic mapping of mu opioid receptor changes in rat brain after long-term haloperidol treatment: relationship to the development of vacuous chewing movements.
    Sasaki T; Kennedy JL; Nobrega JN
    Psychopharmacology (Berl); 1996 Nov; 128(1):97-104. PubMed ID: 8944412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of chronic exercise on reserpine-induced oxidative stress in rats: behavioral and antioxidant evaluations.
    Teixeira AM; Trevizol F; Colpo G; Garcia SC; Charão M; Pereira RP; Fachinetto R; Rocha JB; Bürger ME
    Pharmacol Biochem Behav; 2008 Feb; 88(4):465-72. PubMed ID: 18001823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of buspirone on an animal model of tardive dyskinesia.
    Queiroz CM; Frussa-Filho R
    Prog Neuropsychopharmacol Biol Psychiatry; 1999 Nov; 23(8):1405-18. PubMed ID: 10631766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.
    McCormick SE; Stoessl AJ
    Neuroscience; 2003; 119(2):547-55. PubMed ID: 12770567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Behavioral effects of MK-801 on reserpine-treated mice.
    Dutra RC; Andreazza AP; Andreatini R; Tufik S; Vital MA
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):487-95. PubMed ID: 11999899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.